BioCryst Pharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 65.53 million compared to USD 49.96 million a year ago. Net loss was USD 58.86 million compared to USD 43.2 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.24 a year ago.
For the six months, revenue was USD 115.46 million compared to USD 69.02 million a year ago. Net loss was USD 133.06 million compared to USD 107.48 million a year ago. Basic loss per share from continuing operations was USD 0.72 compared to USD 0.6 a year ago.